Octreotide therapy and restricted fetal growth
pregnancy in familial hyperinsulinemic hypoglycemia

Geilswijk, Marianne; Andersen, Lise Lotte Torvin; Frost, Morten; Brusgaard, Klaus; Beck-Nielsen, Henning; Frederiksen, Anja Lisbeth; Jensen, Dorte Møller

Published in:
Endocrinology, Diabetes & Metabolism Case Reports

DOI:
10.1530/EDM-16-0126

Publication date:
2017

Document version
Final published version

Document license
CC BY-NC-ND

Citation for published version (APA):

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Octreotide therapy and restricted fetal growth: pregnancy in familial hyperinsulinemic hypoglycemia

Marianne Geilswijk1, Lise Lotte Andersen2,4, Morten Frost3,4, Klaus Brusgaard1,4, Henning Beck-Nielsen3,4, Anja Lisbeth Frederiksen1,4 and Dorte Møller Jensen2,3,4

Departments of 1Clinical Genetics, 2Obstetrics, 3Endocrinology, Odense University Hospital, Odense, Denmark, and 4Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark

Summary

Hypoglycemia during pregnancy can have serious health implications for both mother and fetus. Although not generally recommended in pregnancy, synthetic somatostatin analogues are used for the management of blood glucose levels in expectant hyperinsulinemic mothers. Recent reports suggest that octreotide treatment in pregnancy, as well as hypoglycemia in itself, may pose a risk of fetal growth restriction. During pregnancy, management of blood glucose levels in familial hyperinsulinemic hypoglycemia thus forms a medical dilemma. We report on pregnancy outcomes in a woman with symptomatic familial hyperinsulinemic hypoglycemia, type 3. During the patient’s first pregnancy with a viable fetus octreotide treatment was instituted in gestational age 23 weeks to prevent severe hypoglycemic incidences. Fetal growth velocity declined, and at 37 weeks of gestation, intrauterine growth retardation was evident. During the second pregnancy with a viable fetus, blood glucose levels were managed through dietary intervention alone. Thus, the patient was advised to take small but frequent meals high in fiber and low in carbohydrates. Throughout pregnancy, no incidences of severe hypoglycemia occurred and fetal growth velocity was normal. We conclude that octreotide treatment during pregnancy may pose a risk of fetal growth restriction and warrants careful consideration. In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only, also during pregnancy.

Learning points:

- Gain-of-function mutations in GCK cause familial hyperinsulinemic hypoglycemia.
- Hypoglycemia during pregnancy may have serious health implications for mother and fetus.
- Pregnancy with hyperinsulinism represents a medical dilemma as hypoglycemia as well as octreotide treatment may pose a risk of fetal growth restriction.
- In some cases of familial hyperinsulinemic hypoglycemia, blood glucose levels can be successfully managed through diet only.

Background

Familial hyperinsulinemic hypoglycemia type 3 (HHF3, OMIM #602485) is caused by gain-of-function mutations in GCK, the gene encoding glucokinase. In the pancreatic beta cell, glucokinase catalyzes the phosphorylation of glucose to glucose-6-phosphate, which in turn stimulates insulin secretion. Although loss-of-function
GCK mutations cause impaired insulin secretion and mild hyperglycemia, i.e., maturity onset diabetes of young, type 2 (MODY2), activating GCK mutations lead to hyperinsulinism and subsequently hypoglycemia (1). HHF3 is inherited in an autosomal dominant manner and characterized by marked phenotypic variation even within families. In accordance, some heterozygous mutation carriers may only present postprandial hypoglycemia, whereas others experience repeated admissions to hospital due to hypoglycemic convulsions and coma (2, 3).

Animal studies have shown that maternal hyperinsulinism and hypoglycemia during pregnancy increases the risk of fetal malformation and fetal growth restriction (4). Further, it has been hypothesized that incidences of severe maternal hypoglycemia may have damaging impact on the fetal neurological development (5). Although somatostatin analogues may lower insulin secretion and reduce the risk of hyperinsulinemic hypoglycemia, administration of these drugs during pregnancy is generally not recommended due to inadequate data on potential effects on the fetus. Some reports suggest that somatostatin analogues can be used without deleterious effects to the fetus, but recently reservations have been made upon the possible risk of severe fetal growth retardation and likely association to neonatal necrotizing enterocolitis (6, 7, 8).

Hyperinsulinemic hypoglycemia in pregnancy thus forms a medical dilemma as hypoglycemia as well as treatment with somatostatin analogues may cause intrauterine growth retardation. To our knowledge, only two previous publications have addressed this topic (6, 7).

We present pregnancy outcomes in a woman with symptomatic HHF3 treated with octreotide injections in one pregnancy and with a low carbohydrate diet only in a subsequent pregnancy. During the first pregnancy with a viable fetus intrauterine growth retardation (IUGR) developed whilst in the second pregnancy with a viable fetus, fetal growth velocity was normal.

Case presentation

The patient, a thirty-four-year old Caucasian woman, was diagnosed with HHF3 at twenty-three years of age. She was obese with BMI of 34 and smoked 20 cigarettes per day but was otherwise healthy. The patient had no history of severe hypoglycemic episodes, defined as having low blood glucose levels that requires assistance from another person to treat. Yet, she reported intermittent light-headedness, headache and hunger, especially during exercise and when trying to lose weight. In 2004, at the time of diagnosis, pre-prandial blood glucose ranged 1.9–2.7 mmol/L and during oral glucose tolerance test, the blood glucose level was 1.6 mmol/L after 3.5 h with the patient experiencing cold sweat and pronounced discomfort. A 72-h fasting test was initiated but disrupted after only six hours, as blood glucose dropped to 1.9 mmol/L. HbA1c was 4.2% corresponding to 22.4 mmol/mol, and levels of plasma C-peptide (1014 pmol/L) and plasma insulin (88 pmol/L) were increased, whereas plasma pro-insulin was normal (11 pmol/L), suggesting hyperinsulinemic hypoglycemia. Molecular genetic screening identified a heterozygous gain-of-function GCK mutation, c.1367C>T, p.Ala456Val, which had previously been reported in a symptomatic second-degree relative. The patient was recommended a daily calorie intake of 6000–7000 kcal dispersed on 6 meals, high in fiber and with a low glycemic index. Diazoxide therapy was suggested, but the patient declined, as she was unable to accept the possible side effects. Instead, since 2005, she was treated successfully with intramuscular injections of octreotide acetate 10 mg every fourth week to prevent severe hypoglycemia. After treatment was instituted, the patient reported no hypoglycemic symptoms or side effects.

In 2007, she conceived spontaneously but had a missed abortion in gestational week 10. There was no apparent increase in incidences of hypoglycemia leading up to the miscarriage and no conclusions were made upon the cause.

The patient became pregnant for a second time later the same year, and on her request, octreotide was discontinued from gestational age (GA) 11 weeks. Pre-pregnancy BMI was 39, and she smoked 5 cigarettes per day. She was closely followed every fourth week by a dedicated obstetric-endocrine team with self-monitoring of blood glucose profiles and monitoring of fetal growth. At GA 19 weeks, fetal growth was normal and no malformations were identified on ultrasound. From GA 20 weeks, blood glucose dropped below 3.0 mmol/L with increasing frequency and at GA 23 weeks, octreotide therapy was re instituted as the risk of severe hypoglycemia with serious health implications for both patient and fetus was considered significant. Again, the drug was administered as intramuscular injections every fourth week. The initial dosage was octreotide acetate 10 mg with an increase to 20 mg every fourth week from GA 27 weeks. After reinstatement of octreotide acetate injections, the pre-prandial blood glucose levels stabilized >3.0 mmol/L. Fetal ultrasound measurements showed decreasing growth velocity, and at GA 37 weeks, IUGR was diagnosed with fetal biometrics 26% below normal (Fig. 1A). The patient
delivered spontaneously in GA 37+5 weeks after stripping membranes two days earlier. The child had Apgar scores 10 at 1 min and 10 at 5 min, and birth weight and length were 2200 g and 47 cm, respectively. Post-natal molecular genetic testing revealed that the child had not inherited the familial GCK mutation. The patient decided not to breast-feed and octreotide therapy was continued. Data regarding the child's post-natal growth is unfortunately not available.

In 2012, the patient conceived for the third time. An injection of octreotide had been administrated two weeks prior to estimated conception and further administration was discontinued due to the possible risk of impaired fetal growth. A routine sonographic evaluation for nuchal translucency identified a missed abortion corresponding to GA 8+3 years. Octreotide therapy was not re instituted, and the patient managed blood glucose levels through diet only.

In 2013, the patient conceived the fourth time. Her weight was 108 kg, corresponding to a BMI of 40, and she did no longer smoke. At the first visit in the obstetric clinic at GA 8 weeks, she was advised to take small and frequent meals 6 times a day, high in fiber and low in simple carbohydrates. Again, the patient was followed every fourth week to evaluate blood glucose measurements, including blood glucose profiles and HbA1c, and fetal growth. Blood glucose levels were stable between 3.0 and 5.0 mmol/L throughout the first and second trimester (Table 1). In GA 29 weeks, pre-prandial blood glucose dropped below 3 mmol/L, and the diet was adjusted to meals every two hours with 10–12 g of complex carbohydrates and a high content of fiber and fat. During the third trimester, blood glucose levels were predominantly 3.0–4.4 mmol/L with only a few measurements of 2.5–2.9 mmol/L and no

Table 1  Blood glucose profiles during the fourth pregnancy, first trimester.

<table>
<thead>
<tr>
<th>Day</th>
<th>Breakfast Pre</th>
<th>Breakfast Post</th>
<th>Lunch Pre</th>
<th>Lunch Post</th>
<th>Dinner Pre</th>
<th>Dinner Post</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3.6</td>
<td>4.5</td>
<td>4.1</td>
<td>4.9</td>
<td>3.6</td>
<td>4.8</td>
</tr>
<tr>
<td></td>
<td>3.6</td>
<td>4.6</td>
<td>4.4</td>
<td>4.5</td>
<td>3.2</td>
<td>4.2</td>
</tr>
<tr>
<td></td>
<td>3.5</td>
<td>4.4</td>
<td>3.6</td>
<td>3.9</td>
<td>3.0</td>
<td>4.9</td>
</tr>
<tr>
<td></td>
<td>3.3</td>
<td>4.6</td>
<td>3.5</td>
<td>4.0</td>
<td>3.4</td>
<td>4.2</td>
</tr>
<tr>
<td></td>
<td>3.6</td>
<td>4.4</td>
<td>3.6</td>
<td>4.2</td>
<td>3.5</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>3.5</td>
<td>4.3</td>
<td>3.3</td>
<td>4.0</td>
<td>3.2</td>
<td>4.0</td>
</tr>
<tr>
<td></td>
<td>3.6</td>
<td>4.6</td>
<td>3.6</td>
<td>4.1</td>
<td>3.3</td>
<td>4.1</td>
</tr>
<tr>
<td></td>
<td>3.4</td>
<td>4.5</td>
<td>3.4</td>
<td>3.9</td>
<td>3.3</td>
<td>4.2</td>
</tr>
<tr>
<td></td>
<td>3.6</td>
<td>4.4</td>
<td>3.5</td>
<td>4.0</td>
<td>3.5</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>3.7</td>
<td>4.5</td>
<td>3.5</td>
<td>4.0</td>
<td>3.3</td>
<td>4.2</td>
</tr>
<tr>
<td></td>
<td>4.0</td>
<td>4.6</td>
<td>3.7</td>
<td>4.0</td>
<td>3.4</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>3.9</td>
<td>4.2</td>
<td>3.6</td>
<td>4.1</td>
<td>3.5</td>
<td>4.0</td>
</tr>
<tr>
<td></td>
<td>3.4</td>
<td>4.0</td>
<td>3.5</td>
<td>4.0</td>
<td>3.6</td>
<td>4.6</td>
</tr>
<tr>
<td></td>
<td>4.0</td>
<td>4.6</td>
<td>3.5</td>
<td>4.0</td>
<td>3.3</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>4.2</td>
<td>4.8</td>
<td>3.8</td>
<td>4.4</td>
<td>3.4</td>
<td>4.2</td>
</tr>
<tr>
<td></td>
<td>3.4</td>
<td>4.0</td>
<td>3.6</td>
<td>4.0</td>
<td>3.5</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>3.8</td>
<td>4.2</td>
<td>3.7</td>
<td>4.2</td>
<td>3.6</td>
<td>4.1</td>
</tr>
<tr>
<td></td>
<td>3.3</td>
<td>3.9</td>
<td>3.4</td>
<td>4.0</td>
<td>3.1</td>
<td>3.9</td>
</tr>
<tr>
<td></td>
<td>3.1</td>
<td>3.8</td>
<td>3.3</td>
<td>3.9</td>
<td>3.0</td>
<td>3.7</td>
</tr>
<tr>
<td></td>
<td>3.0</td>
<td>3.7</td>
<td>3.2</td>
<td>4.0</td>
<td>3.5</td>
<td>3.9</td>
</tr>
<tr>
<td></td>
<td>3.1</td>
<td>3.6</td>
<td>3.3</td>
<td>3.9</td>
<td>3.4</td>
<td>3.8</td>
</tr>
</tbody>
</table>

Pre: Pre-prandial blood glucose, mmol/L. Post: Post-prandial blood glucose, mmol/L, 1½ hours after meals.

Figure 1  (A) Fetal weight, first pregnancy. Upper and lower red lines marking 97th and third percentiles respectively. (B) Fetal weight, second pregnancy. Upper and lower red line marking 97th and third percentiles respectively.
symptoms of severe hypoglycemia. The fetus showed no signs of IUGR, and fetal growth velocity was normal throughout the second and third trimester (Fig. 1B). After spontaneous labor in GA 39+6 weeks, the patient gave birth to a healthy child with Apgar scores 10 at 1 min and 10 at 10min, and birth weight and length at 2890 g and 48 cm, respectively. Post-natal molecular genetic testing showed that the child did not carry the familial GCK mutation. Data regarding post-natal growth are unfortunately not available.

**Discussion**

Here, we present pregnancy outcomes in a woman with symptomatic HHF3 treated with octreotide injections in the first pregnancy and with a low carbohydrate diet only in a subsequent pregnancy. Two additional pregnancies during octreotide treatment resulted in the 1st trimester spontaneous abortions. During the first pregnancy with a viable fetus, octreotide injections were instituted from GA 23 weeks to maintain blood glucose levels in a normal range and prevent severe hypoglycemic events. A decline in fetal growth velocity was observed from GA 27 weeks, and IUGR was evident at 37 weeks of gestation. In the second pregnancy with a viable fetus blood glucose levels were managed on a low carbohydrate diet only. The fetal growth velocity was normal throughout the pregnancy. The patient did not experience incidences of severe hypoglycemia in any of the pregnancies and HbA1c levels were in the normal range for the second and third trimester pregnancy (Figs 2 and 3) (9). No fetal or umbilical cord malformations were noticed and neither of the children carried the familial gain-of-function GCK mutation. Though the patient smoked up to five cigarettes per day during the first pregnancy, this is unlikely to explain the abrupt decline in fetal growth velocity from the 23rd week of gestation. Instead, the intrauterine growth retardation observed in the first pregnancy may be ascribed to octreotide administration; this factor being the single most important difference between the two pregnancies.

Previous reports on the use of octreotide during pregnancy are scarce and conflicting. Uneventful pregnancies with normal outcomes have been observed in acromegalic women and in one case of unspecified nesidioblastosis (6, 10). Other investigators report on fetal growth retardation and a possible risk of NEC in the neonate after intrauterine octreotide exposure (7, 8). Animal studies on prenatal development report reduced fetal growth and maturation after intrauterine exposure to octreotide. Based on these findings, the drug is generally not recommended for pregnant women (http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sandostatin_LAR_30/WC500169358.pdf. Accessed 27th of March, 2016). Octreotide passes the placental barrier and influence the fetus in the same way as human somatostatin by decreasing levels of insulin and insulin-like growth factor 1 among others (11).

In the present case, the possible damaging effects of octreotide may have been further aggravated as familial hyperinsulinism in itself may increase the risk of IUGR. Skajaa and coworkers proposed that fetal growth in a HHF pregnancy could be influenced by the genetic state of the fetus, analogously to what is seen in MODY2. Our case cannot elucidate this issue, as none of the children were carrying the familial GCK mutation and the genetic status of the aborted fetuses is unknown. Instead, our case indicates that non-carrier fetuses are at risk of growth restriction when exposed to octreotide.

In cases of familial hyperinsulinism, octreotide is used during pregnancy to prevent severe hypoglycemia with the inherent risk of coma and death. Though
hypoglycemia has been associated with both congenital malformations and impaired fetal growth in animal studies, there is no evidence to confirm a similar teratogenic effect of hypoglycemia in pregnancy in humans (4, 5, 12). In adults, recurrent hypoglycemia is associated to a significant decline in cognitive function. Similar findings have not been reported in offspring of diabetic mothers with recurrent hypoglycemic episodes in pregnancy (13). It is speculative whether the more or less constant hypoglycemic state seen in HHF3 affects fetal cognitive development.

Conclusion

Octreotide administration during pregnancy in hyperinsulinism may pose a risk of fetal growth retardation. Other dietary interventions with low carbohydrate content should be considered before octreotide therapy is instituted. Close follow-up of at-risk pregnancies is warranted as hypoglycemia in itself may lead to fetal growth impairment.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent

The patient gave written informed consent for publication of this article.

Author contribution statement

M G drafted the manuscript. L T A, D M J, M F and H B N have all been responsible for the patient's treatment. K B and A L F performed the genetic analysis and interpretation of results. All co-authors, L T A, D M J, M F, H B N, K B and A L F, contributed equally in revising the manuscript.

References